COMPANY
Matrisome Bio
Funding and NIH signals
- NIH award NIH awarded $1.01M (SBIR Phase II 5R44CA298532-02, continuation, notice Aug 7, 2026). NIH RePORTER 5R44CA298532-02 (Aug 7, 2026)
Evidence (1 event)
- Aug 7, 2026 · NIH RePORTER 5R44CA298532-02
Organization: MATRISOME BIO, INC.; City/State: Cambridge, MA; Project number: 5R44CA298532-02; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-08-07; FY total cost (award amount): 1013647; Administering IC: National Cancer Institute; Project title: Development of an extracellular matrix-targeted theranostic radiopharmaceutical for metastatic lung cancer; Organization type: Domestic For-Profits
- Aug 7, 2026 · NIH RePORTER 5R44CA298532-02